Vinay Prasad on Biotech Profiting From Ineffective Drugs: warns against

What Prasad says

Dr. Vinay Prasad warns that the current system lets companies profit from ineffective drugs — his framing is “why biotech can make money on bad drugs.” He makes the case in the Get the Check podcast interview (~August 2026, timestamp ~47:57), pointing to perverse incentives in how drugs are approved and paid for.

His stated reasoning

Prasad’s stated reasoning is that when approval standards are weak and prices are disconnected from proven benefit, companies can earn large returns on products that don’t help patients. Fixing the incentives, he says, means demanding evidence of real benefit before the money flows.

This page chronicles a stated position of the person above. It is not medical advice and not the site's own conclusion.